Related Experiment Video
Updated: May 4, 2026
Author Spotlight: Expanding Interventional Pulmonology Research with Robotic-Assisted Bronchoscopy
Published on: July 19, 2024
Experimental study of Endostar injection concomitant with cryoablation on lung adenocarcinoma A549 xenografts
Chun-Hua Ma1, Rong Jiang, Jin-Duo Li
1Department of Intervention, Tianjin Huanhu Hospital, Tianjin Cerebral Vascular and Neural Degenerative Disease Key Laboratory, Tianjin, China
Objective:
To explore the inhibiting effect and mechanism of Endostar injection concomitant with cryoablation on lung adenocarcinoma A549 xenografts in nude mice.
Materials And Methods:
A total of 24 nude mice with subcutaneous xenografts of the A549 cell line were established and divided into 4 groups when the maximal diameters of tumors became 1 cm: control group, Endostar group, cryoablation group and combination group (Endostar concomitant with cryoablation). The nude mice were sacrificed after 21-days treatment, tumour tissues were removed to measure their volume, in situ test of TdT-mediated dUTP nick end labeling (TUNEL) was adopted to determine the cellular apoptosis around freezing injury zones, and immunohistochemical SP test was applied for the detection of micro-vessel density (MVD) and vascular endothelial growth factor (VEGF) expression levels.
Results:
At 21-days after treatment, the growth velocities of control group, Endostar group, cryoablation group and combination group were 236.7 ± 51.2%, 220.0 ± 30.6%, 159.5 ± 29.3% and 103.3 ± 25.5% (P<0.01), while cellular apoptosis rates of tumors were 21.7 ± 2.34%, (22.17 ± 1.47)%, 38.3 ± 1.37% and 49.2 ± 1.72%, (P<0.01), respectively, according to the immunohistochemical test. MVD and VEGF expression levels in the combination group were both lower than in other groups (P<0.01), also being positively related (r=0.925, P<0.01).
Conclusions:
Endostar can significantly improve the inhibitory effects of cryoablation on xenografts of lung adenocarcinoma A549, and the mechanism is probably associated with its function as an inhibitor of tumour neo-angiogenesis through down-regulating VEGF expression.
Insights
Endostar combined with cryoablation significantly inhibits lung adenocarcinoma growth by increasing apoptosis and reducing tumor angiogenesis. This combination therapy offers a promising approach for treating A549 lung cancer xenografts.
Area of Science:
- Oncology
- Cancer Research
- Experimental Therapeutics
Background:
- Lung adenocarcinoma is a major cause of cancer mortality.
- Novel therapeutic strategies are needed to improve treatment outcomes.
- Cryoablation and Endostar are potential treatments for lung adenocarcinoma.
Purpose of the Study:
- To investigate the combined effect of Endostar and cryoablation on lung adenocarcinoma A549 xenografts.
- To elucidate the underlying mechanisms of this combined therapy.
Main Methods:
- A549 lung adenocarcinoma xenografts were established in nude mice.
- Mice were divided into control, Endostar, cryoablation, and combination groups.
- Tumor growth, apoptosis (TUNEL), micro-vessel density (MVD), and VEGF expression were assessed.
Main Results:
- The combination group showed significantly reduced tumor growth velocity (103.3 ± 25.5%) compared to other groups (P<0.01).
- Cellular apoptosis rates were highest in the combination group (49.2 ± 1.72%, P<0.01).
- MVD and VEGF expression levels were significantly lower in the combination group (P<0.01).
Conclusions:
- Endostar enhances the inhibitory effects of cryoablation on lung adenocarcinoma xenografts.
- The mechanism involves inhibiting tumor neo-angiogenesis by down-regulating VEGF expression.
